Welcome to BioSeeker Group!

Antifungals: 2004 and Beyond

Additional Information

Published Date Oct 19, 2004
Pages 79
PDF Fact Sheet View Fact Sheet for the report Antifungals: 2004 and Beyond in PDF
Format PDF
Publisher BioSeeker Group

Availability: In stock

$1,950.00

Quick Overview

Overview of the most common fungal diseases, already marketed antifungal agents, details from recent studies on approved agents, and information on the recent activities of companies with developmental antifungals.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Antifungals: 2004 and Beyond.

    To find out more about Antifungals: 2004 and Beyond, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Antifungals: 2004 and Beyond is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

The market for antifungal agents continues to grow. According to an article in BioBN, "the worldwide market for treatment of invasive fungal infections is estimated to reach $2.4 billion in 2003 and to grow to $3.1 billion in 2008." Diflucan, the world’s leading systemic antifungal, alone had sales of $1.176 billion in 2003. The growth of the antifungal market is due to several factors: 1) an increase in the number of people living in an immunocompromised state which makes them more susceptible to fungal infections 2) fungi are becoming increasingly resistant to standard therapies 3) many of the standard therapies have a high toxicity and/or significant adverse events which results in a need for more efficacious antifungals. One recent statistic from March 2004 claimed that "Out of nine million patients at-risk, 1.2 million will go on to develop fungal infections." Furthermore, according to the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, "within the last 5 years, infections due to clinically relevant fungi such as Candida, Aspergillus, and Fusarium have come to the forefront as common and significant causes of morbidity and mortality in immunocompromised patients."4 Thus, having an arsenal of effective antifungal agents to address fungal infections is of growing importance.

In this report, BioSeeker provides an overview of the most common fungal diseases, already marketed antifungal agents, details from recent studies on approved agents, and information on the recent activities of companies with developmental antifungals. More and more companies have become attracted to the antifungal market in the past decade for the following reasons: to address the unmet needs of an increasing patient population, to develop new compounds that can combat the fungi that have grown resistant to standard therapies, and to meet the challenges of reducing negative side effect profiles. This report explores the recent research on developmental compounds as well as life cycle management initiatives for existing therapies. As more antifungals become available, it will be increasingly important to determine which agents are the most effective against specific infections and to identify the ideal treatment protocols for each respective infection.

This 77-page report covers events that have occurred since May 2003 in the antifungal industry. Furthermore, the report only focuses on antifungal agents that are in phase III clinical trials and beyond. A complementary report discussing antifungal development pre-phase III will be published shortly.

Executive Summary
Topics considered in this report
Companies mentioned in this report
Methodology
Information Sources
Analysts
Introduction
Antifungal Overview
Fungal Diseases
Risk Factors for Fungal Diseases
Antifungal Agents
Structure and Mechanism of Action
Treatment Alternatives
Indications and Side Effects Table
Research Findings
Albaconazole
Amphotericin B
Anidulafungin
Caspofungin
Clotrimazole/Eberconazole
Fluconazole
Itraconazole
Ketoconazole
Micafungin
Miconazole
Posaconazole
Ravuconazole
Terbinafine
Voriconazole
Other General Findings
Company Activities
New Drug Applications (NDAs)
Abbreviated New Drug Applications (ANDAs)
Approvals
Research Collaborations
Mergers and Acquisitions
Court Rulings
Knowledge Leaders
Conclusions
Index
Disclaimer
References

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Antifungals: 2004 and Beyond.
    To find out more about Antifungals: 2004 and Beyond, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Antifungals: 2004 and Beyond is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'R&D' category:


Target Atlas in Thyroid Cancer: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More


Notch Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 335 companies plus partners who are today developing 416 Notch pathway targeting drugs in 1497 developmental projects in cancer across 232 different targets. In addition, there are 4 suspended drugs and another 236 drugs where development has been ceased. Learn More

Other selected research from the 'Infectious diseases' category:


Competitive Outlook on HCV: What to Know and Expect in R&D and Business Development
A fresh look on both the current world status of R&D and business development in HCV. Our research and analysis is built on more than 150 companies from over 18 different countries and include more than 160 pipline drugs in development for HCV. Learn More


Market Development in Anti-virals:What is Next?
This analysis deals with 26 of the most promising pharmaceutical companies with anti-viral drugs on the market. Indication by indication is measured by number of current therapies, present sales and sales development. Learn More